An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Improves Quality of Life in Psoriasis: Results from a Phase 2 Study. J of Skin 2019, 3, S12. https://doi.org/10.25251/skin.3.supp.12.